AnaptysBio (NASDAQ:ANAB) Trading 6.5% Higher – Still a Buy?

AnaptysBio, Inc. (NASDAQ:ANAB) rose 6.5% during trading on Monday . The company traded as high as $35.70 and last traded at $35.37. Approximately 130,450 shares changed hands during trading, a decline of 60% from the average daily volume of 324,622 shares. The stock had previously closed at $33.22.

Wall Street Analysts Forecast Growth

ANAB has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, September 26th. JPMorgan Chase & Co. boosted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Truist Financial boosted their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.10.

AnaptysBio Stock Performance

The stock has a market cap of $949.06 million, a PE ratio of -5.76 and a beta of -0.29. The stock has a fifty day simple moving average of $35.22 and a two-hundred day simple moving average of $28.94.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. On average, equities analysts predict that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $35.00, for a total value of $52,500.00. Following the transaction, the insider now directly owns 11,618 shares of the company’s stock, valued at $406,630. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now directly owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now directly owns 11,618 shares in the company, valued at approximately $406,630. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,940 shares of company stock valued at $945,436 in the last three months. Corporate insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Duncan Williams Asset Management LLC acquired a new stake in shares of AnaptysBio during the 3rd quarter valued at approximately $282,000. SG Americas Securities LLC acquired a new stake in AnaptysBio in the third quarter worth $405,000. Algert Global LLC increased its position in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,078 shares during the period. Frazier Life Sciences Management L.P. increased its position in AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after buying an additional 1,265,891 shares during the period. Finally, Susquehanna Fundamental Investments LLC increased its position in AnaptysBio by 32.9% in the second quarter. Susquehanna Fundamental Investments LLC now owns 72,060 shares of the biotechnology company’s stock worth $1,806,000 after buying an additional 17,855 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.